Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Henlius HLX10-020-SCLC302

Trial Overview

Official Title

Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Study Purpose

To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation. 

 

Diagnosis

Limited stage small cell lung cancer (LS-SCLC)

Eligibility

Unresectable stage I-III patients able to be safely treated with curative radiation. 

 

Intervention

Experimental arm: HLX10 plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation

Control arm: placebo plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation

For more information visit

Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Pending
Phase
Phase III